Original Research
Published on 02 Apr 2025
Dynamic risk stratification and treatment optimization in sepsis: the role of NLPR
in Inflammation Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1572677
- 109 views
Type at least 3 characters
1,716 articles
Editorial
Accepted on 01 Apr 2025
Editorial: Targeting Neuroinflammation for Novel Therapeutics in Neurodegenerative Diseases
in Inflammation Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1602495
Original Research
Accepted on 01 Apr 2025
The immunostimulatory activity of Epimedium flavonoids involves Toll-like receptor 7/8
in Inflammation Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1514284
Original Research
Accepted on 01 Apr 2025
URINARY URODILATIN LEVELS IN PATIENTS WITH RENAL SALT WASTING SYNDROME AS A POSSIBLE NEW DIAGNOSTIC MARKER. A PILOT STUDY
in Inflammation Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1579699
Original Research
Published on 01 Apr 2025
Metal-phenolic nanozyme as a ferroptosis inhibitor for alleviating cisplatin-induced acute kidney injury
in Inflammation Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1535969
- 169 views
Original Research
Published on 01 Apr 2025
A real-world pharmacovigilance analysis of omadacycline in FDA adverse event reporting system (FAERS) database
in Inflammation Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1558868
- 107 views
Clinical Trial
Published on 01 Apr 2025
First-in-human study of CPL’116 – a dual JAK/ROCK inhibitor – in healthy subjects
in Inflammation Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1583723
- 255 views
Review
Published on 01 Apr 2025
Region-specific mitophagy in nucleus pulposus, annulus fibrosus, and cartilage endplate of intervertebral disc degeneration: mechanisms and therapeutic strategies
in Inflammation Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1579507
Original Research
Published on 01 Apr 2025
Dexmedetomidine alleviates lung ischemia-reperfusion injury by inhibiting cuproptosis: an in vivo study
in Inflammation Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1562535
Original Research
Accepted on 31 Mar 2025
Umbilical cord stem cells therapy against bacterial pneumonia based on zebrafish pneumonia model
in Inflammation Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1546193
Original Research
Accepted on 27 Mar 2025
Exploring the mechanism of Triptolide inhibiting the motility of fibroblast-like synoviocytes in rheumatoid arthritis via RhoA/Rho-associated kinase axis, based on network pharmacology, molecular docking and molecular dynamics simulations
in Inflammation Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1545514
Original Research
Published on 27 Mar 2025
Homoplantaginin exerts therapeutic effects on intervertebral disc degeneration by alleviating TNF-α-induced nucleus pulposus cell senescence and inflammation
in Inflammation Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1526107
- 136 views
Original Research
Accepted on 26 Mar 2025
Frailty and cardiovascular safety of JAK inhibitors versus TNF inhibitors in rheumatoid arthritis: real-world comparative study of drug effects and patients' profile.
in Inflammation Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1565909
Original Research
Published on 26 Mar 2025
Senecio scandens Buch.-Ham. polysaccharides exert anti-atopic dermatitis effects by modulating gut microbiota and the MAPK/NF-ÎşB pathway
in Inflammation Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1573135
- 153 views
Original Research
Published on 25 Mar 2025
Phenylethyl isothiocyanate mitigates drug-induced liver injury in mice by inhibiting hepatocyte pyroptosis through the NLRP3-caspase-1-GSDMD pathway
in Inflammation Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1539934
- 212 views
Review
Accepted on 24 Mar 2025
The emerging role of vascular endothelial cell-mediated angiogenesis in the imbalance of RA synovial microenvironment and its clinical relevance
in Inflammation Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1481089